ROCKVILLE, Md., Feb. 09, 2024 MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of.
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 .